Juan Pablo Horcajada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2333909/publications.pdf

Version: 2024-02-01

228 papers

15,650 citations

25423 59 h-index 23841 115 g-index

250 all docs

250 docs citations

250 times ranked

22355 citing authors

#	Article	IF	CITATIONS
1	Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review. Expert Review of Anti-Infective Therapy, 2022, 20, 179-197.	2.0	9
2	Aminoglycoside or Polymyxin Monotherapy for Treating Complicated Urinary Tract Infections Caused by Extensively Drug-Resistant Pseudomonas aeruginosa: A Propensity Score-Adjusted and Matched Cohort Study. Infectious Diseases and Therapy, 2022, 11, 335-350.	1.8	8
3	A Descriptive Analysis of Urinary ESBL-Producing-Escherichia coli in Cerdanya Hospital. Microorganisms, 2022, 10, 488.	1.6	5
4	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS. Clinical Epidemiology, 2022, Volume 14, 369-384.	1.5	11
5	A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of the Monoclonal Antibody MHAA4549A in Patients With Acute Uncomplicated Influenza A Infection. Open Forum Infectious Diseases, 2022, 9, ofab630.	0.4	3
6	Comparison of Hospitalized Coronavirus Disease 2019 and Influenza Patients Requiring Supplemental Oxygen in a Cohort Study: Clinical Impact and Resource Consumption. Clinical Infectious Diseases, 2022, 75, 2225-2238.	2.9	2
7	Preoperative and perioperative risk factors, and risk score development for prosthetic joint infection due to Staphylococcus aureus: a multinational matched case-control study. Clinical Microbiology and Infection, 2022, 28, 1359-1366.	2.8	4
8	A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia. Expert Review of Clinical Pharmacology, 2022, 15, 671-688.	1.3	2
9	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. Clinical Infectious Diseases, 2021, 73, e3647-e3655.	2.9	75
10	Executive summary of the Consensus Document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and of the Spanish Association of Surgeons (AEC) in antibiotic prophylaxis in surgery. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2021, 39, 29-40.	0.3	8
11	Azithromycin in the treatment of COVID-19: a review. Expert Review of Anti-Infective Therapy, 2021, 19, 147-163.	2.0	167
12	Evolution of Antimicrobial Consumption During the First Wave of COVID-19 Pandemic. Antibiotics, 2021, 10, 132.	1.5	56
13	SARSâ€CoVâ€2 sculpts the immune system to induce sustained virusâ€specific naÃveâ€like and memory Bâ€cell responses. Clinical and Translational Immunology, 2021, 10, e1339.	1.7	11
14	Economic burden of recurrent Clostridioides difficile infection in adults admitted to Spanish hospitals. A multicentre retrospective observational study. Revista Espanola De Quimioterapia, 2021, 34, 126-135.	0.5	5
15	Osteoarticular Cryptococcosis Successfully Treated with High-Dose Liposomal Amphotericin B Followed by Oral Fluconazole. Infection and Drug Resistance, 2021, Volume 14, 719-722.	1.1	5
16	Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection. Nutrients, 2021, 13, 562.	1.7	73
17	Epigenome-wide association study of COVID-19 severity with respiratory failure. EBioMedicine, 2021, 66, 103339.	2.7	90
18	Efficacy and Safety of Oral Fosfomycin for Asymptomatic Bacteriuria in Kidney Transplant Recipients: Results from a Spanish Multicenter Cohort. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	4

#	Article	IF	CITATIONS
19	Risk Factors for Amoxicillin-Clavulanate Resistance in Community-Onset Urinary Tract Infections Caused by Escherichia coli or Klebsiella pneumoniae: The Role of Prior Exposure to Fluoroquinolones. Antibiotics, 2021, 10, 582.	1.5	8
20	Impact of a Nosocomial COVID-19 Outbreak on a Non-COVID-19 Nephrology Ward during the First Wave of the Pandemic in Spain. Antibiotics, 2021, 10, 619.	1.5	4
21	Hospital-at-Home Expands Hospital Capacity During COVID-19 Pandemic. Journal of the American Medical Directors Association, 2021, 22, 939-942.	1.2	24
22	Clinical and Economic Impact of Community-Onset Urinary Tract Infections Caused by ESBL-Producing Klebsiella pneumoniae Requiring Hospitalization in Spain: An Observational Cohort Study. Antibiotics, 2021, 10, 585.	1.5	8
23	Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity. Antimicrobial Agents and Chemotherapy, 2021, 65, .	1.4	12
24	Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis. Clinical Microbiology and Infection, 2021, 27, 1631-1637.	2.8	36
25	Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia: A Cohort Study. Antibiotics, 2021, 10, 716.	1.5	5
26	Coronavirus disease 2019 (COVID-19) mRNA vaccine effectiveness in asymptomatic healthcare workers. Infection Control and Hospital Epidemiology, 2021, , 1-2.	1.0	7
27	Impact and Management of COVID-19 Among Healthcare Workers in Two Acute Care Hospitals and Two Associated Long-term Care Centres in Barcelona, Spain. Journal of Occupational and Environmental Medicine, 2021, 63, e586-e591.	0.9	2
28	Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19. JAMA - Journal of the American Medical Association, 2021, 326, 499.	3.8	498
29	Antimicrobial Consumption among 66 Acute Care Hospitals in Catalonia: Impact of the COVID-19 Pandemic. Antibiotics, 2021, 10, 943.	1.5	36
30	Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates. Microbiology Spectrum, 2021, 9, e0058521.	1.2	18
31	Resumen ejecutivo del Documento de Consenso de la Sociedad Española de Enfermedades Infecciosas y MicrobiologÃa ClÃnica (SEIMC) y de la Asociación Española de Cirujanos (AEC) en profilaxis antibiótica en cirugÃa. CirugÃa Española, 2021, 99, 11-26.	0.1	6
32	OUP accepted manuscript. Glycobiology, 2021, 31, 372-377.	1.3	27
33	Ceftolozane-tazobactam: When, how and why using it?. Revista Espanola De Quimioterapia, 2021, 34, 35-37.	0.5	6
34	A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?. Infectious Diseases and Therapy, 2021, 10, 2677-2699.	1.8	4
35	Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality. Antibiotics, 2021, 10, 1296.	1.5	4
36	Intraoperative Bacterial Contamination and Activity of Different Antimicrobial Prophylaxis Regimens in Primary Knee and Hip Replacement. Antibiotics, 2021, 10, 18.	1.5	7

#	Article	IF	Citations
37	Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Scientific Reports, 2021, 11, 22178.	1.6	6
38	Oral fosfomycin for the treatment of lower urinary tract infections among kidney transplant recipients—Results of a Spanish multicenter cohort. American Journal of Transplantation, 2020, 20, 451-462.	2.6	15
39	Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. Journal of Antimicrobial Chemotherapy, 2020, 75, 618-627.	1.3	60
40	Protection of nephrology health professionals during the COVID-19 pandemic. Nefrologia, 2020, 40, 395-401.	0.2	8
41	Trends of Adult Antimicrobial Hospital Consumption in Catalonia (Spain) from 2008 to 2018. Infection Control and Hospital Epidemiology, 2020, 41, s500-s501.	1.0	0
42	Characteristics and predictors of death among 4035 consecutively hospitalized patients with COVID-19 in Spain. Clinical Microbiology and Infection, 2020, 26, 1525-1536.	2.8	249
43	ProtecciÃ ³ n de los profesionales sanitarios en nefrologÃa ante la pandemia por COVID-19. Nefrologia, 2020, 40, 395-402.	0.2	8
44	Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain. Archivos De Bronconeumologia, 2020, 56, 756-758.	0.4	56
45	Impact of changes in the WHO's 2019 update of DDDs on the measurement of adult hospital antibacterial consumption in Catalonia (Spain), 2008–18. JAC-Antimicrobial Resistance, 2020, 2, dlaa079.	0.9	2
46	Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,749
47	Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science, 2020, 370, .	6.0	1,983
48	COVID-19 in Grade 4–5 Chronic Kidney Disease Patients. Kidney and Blood Pressure Research, 2020, 45, 768-774.	0.9	15
49	Clinical Profiles in Renal Patients with COVID-19. Journal of Clinical Medicine, 2020, 9, 2665.	1.0	16
50	Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain. Archivos De Bronconeumologia, 2020, 56, 756-758.	0.4	21
51	Efficacy of Ceftolozane-Tazobactam in Combination with Colistin against Extensively Drug-Resistant Pseudomonas aeruginosa, Including High-Risk Clones, in an <i>In Vitro</i> Pharmacodynamic Model. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	8
52	COVID-19 in elderly kidney transplant recipients. American Journal of Transplantation, 2020, 20, 2883-2889.	2.6	64
53	Risk Factors for Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: What Is the Influence of XDR Phenotype on Outcomes?. Journal of Clinical Medicine, 2020, 9, 514.	1.0	27
54	Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Critical Care, 2020, 24, 55.	2.5	34

#	Article	IF	Citations
55	Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic \hat{l}^2 -Lactam-Resistant Mutants. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	54
56	Budget Impact Analysis of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in Three European Countries. Clinical Drug Investigation, 2020, 40, 305-318.	1.1	15
57	Clinical and economic burden of community-onset multidrug-resistant infections requiring hospitalization. Journal of Infection, 2020, 80, 271-278.	1.7	10
58	Pathogenesis of Staphylococcus epidermidis in prosthetic joint infections: can identification of virulence genes differentiate between infecting and commensal strains?. Journal of Hospital Infection, 2020, 105, 561-568.	1.4	6
59	Management of the SARS-CoV-2 (COVID-19) coronavirus epidemic in hemodialysis units. Nefrologia, 2020, 40, 258-264.	0.2	19
60	Effects of Environmental Factors on Severity and Mortality of COVID-19. Frontiers in Medicine, 2020, 7, 607786.	1.2	40
61	Fosfomycin Trometamol versus Comparator Antibiotics for the Treatment of Acute Uncomplicated Urinary Tract Infections in Women: A Systematic Review and Meta-Analysis. Journal of Urology, 2020, 203, 570-578.	0.2	21
62	Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	33
63	Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spaish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR). Revista Espanola De Ouimioterapia. 2020. 33. 151-175.	0.5	13
64	Reply by Authors. Journal of Urology, 2020, 203, 578-578.	0.2	1
65	Infection Control, Antimicrobial Consumption, and Hospital-Acquired Clostridioides difficile Infection in Acute-Care Hospitals in Catalonia. Infection Control and Hospital Epidemiology, 2020, 41, s483-s484.	1.0	O
66	A Prevention Initiative to Reduce Healthcare-Associated Bloodstream Infections in a Spanish University Hospital. Infection Control and Hospital Epidemiology, 2020, 41, s455-s456.	1.0	0
67	Improvement of Adequacy of Empirical Antimicrobial Therapy in Escherichia coli Bacteremia of Urinary Source in Catalonia (VINCat-PROA). Infection Control and Hospital Epidemiology, 2020, 41, s483-s483.	1.0	0
68	Relationship Between Biofilm Formation and Antimicrobial Resistance in Gram-Negative Bacteria. Microbial Drug Resistance, 2019, 25, 72-79.	0.9	192
69	Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey. Journal of Antimicrobial Chemotherapy, 2019, 74, 3217-3220.	1.3	18
70	Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. Journal of Infection, 2019, 79, 253-261.	1.7	28
71	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. Transplant Infectious Disease, 2019, 21, e13195.	0.7	14
72	DELAFLOXACIN IN THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA: OUTCOMES FROM A GLOBAL PHASE-3 STUDY. Chest, 2019, 156, A412-A413.	0.4	0

#	Article	IF	CITATIONS
73	TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA IN PATIENTS WITH RENAL IMPAIRMENT: OUTCOMES FROM A GLOBAL PHASE-3 STUDY OF DELAFLOXACIN. Chest, 2019, 156, A1132.	0.4	O
74	Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clinical Microbiology Reviews, 2019, 32, .	5.7	489
75	Linezolid vs glycopeptides in the treatment of glycopeptide-susceptible Enterococcus faecium bacteraemia: A propensity score matched comparative study. International Journal of Antimicrobial Agents, 2019, 54, 572-578.	1.1	8
76	Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. Journal of Antimicrobial Chemotherapy, 2019, 74, 3268-3273.	1.3	12
77	Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones. Journal of Global Antimicrobial Resistance, 2019, 18, 37-44.	0.9	16
78	Population Pharmacokinetics of Anidulafungin in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	12
79	The Different Microbial Etiology of Prosthetic Joint Infections according to Route of Acquisition and Time after Prosthesis Implantation, Including the Role of Multidrug-Resistant Organisms. Journal of Clinical Medicine, 2019, 8, 673.	1.0	79
80	Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology. Journal of Antimicrobial Chemotherapy, 2019, 74, 1825-1835.	1.3	92
81	Economic evaluation of the treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) from the national payer perspective: introduction of a new treatment to the patient journey. A simulation of three European countries. Expert Review of Pharmacoeconomics and Outcomes Research. 2019. 19, 581-599.	0.7	12
82	Colistin Use in Patients with Chronic Kidney Disease: Are We Underdosing Patients?. Molecules, 2019, 24, 530.	1.7	7
83	A Phase-3 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults with Community-acquired Bacterial Pneumonia (DEFINE-CABP). Open Forum Infectious Diseases, 2019, 7, ofz514.	0.4	26
84	Linezolid Dosing in Patients With Liver Cirrhosis: Standard Dosing Risk Toxicity. Therapeutic Drug Monitoring, 2019, 41, 732-739.	1.0	17
85	Rhodomyrtone decreases Staphylococcus aureus SigB activity during exponentially growing phase and inhibits haemolytic activity within membrane vesicles. Microbial Pathogenesis, 2019, 128, 112-118.	1.3	11
86	Risk of hospital readmission and associated factors after a positive sample for a multidrug-resistant microorganism. European Journal of Public Health, 2019, 29, 981-986.	0.1	2
87	High-dose benznidazole in a 62-year-old Bolivian kidney transplant recipient with Chagas central nervous system involvement. International Journal of Infectious Diseases, 2019, 78, 103-106.	1.5	9
88	General Assembly, Treatment, Antimicrobials: Proceedings of International Consensus on Orthopedic Infections. Journal of Arthroplasty, 2019, 34, S225-S237.	1.5	15
89	Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection. JAMA - Journal of the American Medical Association, 2018, 319, 788.	3 . 8	236
90	Diagnosis and management of asymptomatic bacteriuria in kidney transplant recipients: a survey of current practice in Europe. Nephrology Dialysis Transplantation, 2018, 33, 1661-1668.	0.4	32

#	Article	IF	Citations
91	Antibiotic treatment of infections caused by carbapenem-resistant Gram-negative bacilli: an international ESCMID cross-sectional survey among infectious diseases specialists practicing in large hospitals. Clinical Microbiology and Infection, 2018, 24, 1070-1076.	2.8	58
92	Trends in AIDS Mortality, Retention in Opioid Agonist Therapy, and HIV RNA Suppression in HIV-Infected People Who Injected Drugs from 2000 to 2015. AIDS and Behavior, 2018, 22, 2766-2772.	1.4	1
93	A Before-and-After Study of the Effectiveness of an Antimicrobial Stewardship Program in Critical Care. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	37
94	Epidemiology of Prosthetic Joint Infection. , 2018, , 5-53.		2
95	Metabolomic Profile of ARDS by Nuclear Magnetic Resonance Spectroscopy in Patients With H1N1 Influenza Virus Pneumonia. Shock, 2018, 50, 504-510.	1.0	22
96	Evaluation of Ceftolozane-Tazobactam in Combination with Meropenem against Pseudomonas aeruginosa Sequence Type 175 in a Hollow-Fiber Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	21
97	Multinational case-control study of risk factors for the development of late invasive pulmonary aspergillosis following kidney transplantation. Clinical Microbiology and Infection, 2018, 24, 192-198.	2.8	25
98	Dalbavancin in the treatment of different gram-positive infections: a real-life experience. International Journal of Antimicrobial Agents, 2018, 51, 571-577.	1.1	125
99	Antimicrobial stewardship in Spain: Programs for Optimizing the use of Antibiotics (PROA) in Spanish hospitals. Germs, 2018, 8, 109-112.	0.5	7
100	Characterization and rapid control of a vancomycin-resistant Enterococcus faecium (VREF) outbreak in a renal transplant unit in Spain: The environment matters. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 5-11.	0.3	6
101	Impact of colistin plasma levels on the clinical outcome of patients with infections caused by extremely drug-resistant Pseudomonas aeruginosa. BMC Infectious Diseases, 2017, 17, 11.	1.3	34
102	Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2017, 35, 189-195.	0.3	79
103	Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	15
104	The Not-So-Good Prognosis of Streptococcal Periprosthetic Joint Infection Managed by Implant Retention: The Results of a Large Multicenter Study. Clinical Infectious Diseases, 2017, 64, 1742-1752.	2.9	97
105	Executive summary of management of prosthetic joint infections. Clinical practice guidelines by the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2017, 35, 189-195.	0.2	11
106	C-reactive protein may misdiagnose prosthetic joint infections, particularly chronic and low-grade infections. International Orthopaedics, 2017, 41, 1315-1319.	0.9	110
107	Daptomycin use: where is the truth? Authors' response. Future Microbiology, 2017, 12, 13-14.	1.0	0
108	Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain. Antimicrobial Agents and Chemotherapy, 2017, 61, .	1.4	108

#	Article	IF	CITATIONS
109	Discriminant biomarkers of acute respiratory distress syndrome associated to H1N1 influenza identified by metabolomics HPLCâ€QTOFâ€MS/MS platform. Electrophoresis, 2017, 38, 2341-2348.	1.3	12
110	Daptomicina a dosis elevadas y rifampicina como tratamiento de rescate para infecciones protésicas. Medicina ClÃnica, 2017, 149, 223-224.	0.3	3
111	Impact of probiotic Saccharomyces boulardii on the gut microbiome composition in HIV-treated patients: A double-blind, randomised, placebo-controlled trial. PLoS ONE, 2017, 12, e0173802.	1.1	46
112	Virulence genes and subclone status as markers of experimental virulence in a murine sepsis model among Escherichia coli sequence type 131 clinical isolates from Spain. PLoS ONE, 2017, 12, e0188838.	1.1	7
113	Validation Protocol of Vitamin D Supplementation in Patients with HIV-Infection. AIDS Research and Treatment, 2016, 2016, 1-8.	0.3	9
114	Brief Report: HIV Infection Is Associated With Worse Bone Material Properties, Independently of Bone Mineral Density. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 314-318.	0.9	35
115	Clinical Presentation and Determinants of Mortality of Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: A Multinational Cohort Study. American Journal of Transplantation, 2016, 16, 3220-3234.	2.6	57
116	Risk Factors Associated With Early Invasive Pulmonary Aspergillosis in Kidney Transplant Recipients: Results From a Multinational Matched Case–Control Study. American Journal of Transplantation, 2016, 16, 2148-2157.	2.6	39
117	Urinary micafungin levels are sufficient to treat urinary tract infections caused by Candida spp International Journal of Antimicrobial Agents, 2016, 48, 212-214.	1.1	25
118	Drug treatments for prosthetic joint infections in the era of multidrug resistance. Expert Opinion on Pharmacotherapy, 2016, 17, 1233-1246.	0.9	21
119	Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. International Journal of Antimicrobial Agents, 2016, 48, 725-727.	1.1	50
120	Preoperative antibiotic prophylaxis in prosthetic joint infections: not a concern for intraoperative cultures. Diagnostic Microbiology and Infectious Disease, 2016, 86, 442-445.	0.8	36
121	Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial. International Journal of Antimicrobial Agents, 2016, 48, 310-316.	1.1	73
122	IFITM3 and severe influenza virus infection. No evidence of genetic association. European Journal of Clinical Microbiology and Infectious Diseases, 2016, 35, 1811-1817.	1.3	33
123	CTX-M-15- <i>H</i> 30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producing <i>Escherichia coli</i> bacteraemia of urinary origin in Spain. Journal of Antimicrobial Chemotherapy, 2016, 71, 2125-2130.	1.3	46
124	Enterococcal bloodstream infection. Design and validation of a mortality prediction rule. International Journal of Clinical Practice, 2016, 70, 147-155.	0.8	6
125	Clinical characteristics, treatment and outcomes of MRSA bacteraemia in the elderly. Journal of Infection, 2016, 72, 309-316.	1.7	11
126	Ãndice de masa corporal elevado como factor de riesgo de hospitalización por gripe: estudio de casos y controles. Archivos De Bronconeumologia, 2016, 52, 299-307.	0.4	16

#	Article	IF	Citations
127	Pharmacokinetics of micafungin in patients with pre-existing liver dysfunction: A safe option for treating invasive fungal infections. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2016, 34, 652-654.	0.3	8
128	Clinical features and outcomes of tuberculosis in transplant recipients as compared with the general population: a retrospective matched cohort study. Clinical Microbiology and Infection, 2015, 21, 651-658.	2.8	41
129	Risk factors for severe sepsis in community-onset bacteraemic urinary tract infection: Impact of antimicrobial resistance in a large hospitalised cohort. Journal of Infection, 2015, 70, 247-254.	1.7	17
130	Diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 337.e1-337.e21.	0.3	29
131	Executive summary of the diagnosis and antimicrobial treatment of invasive infections due to multidrug-resistant Enterobacteriaceae. Guidelines of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC). Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2015, 33, 338-341.	0.3	23
132	Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. Journal of Infection, 2015, 71, 385-394.	1.7	39
133	Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. Clinical Microbiology and Infection, 2015, 21, 491.e1-491.e10.	2.8	57
134	Optimización de los aislamientos preventivos en una UCI polivalente mediante la aplicación de un plan de intervención. Medicina Intensiva, 2015, 39, 543-551.	0.4	4
135	A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. Clinical Microbiology and Infection, 2015, 21, 684.e1-684.e9.	2.8	19
136	Improved Diagnosis of Orthopedic Implant-Associated Infection by Inoculation of Sonication Fluid into Blood Culture Bottles. Journal of Clinical Microbiology, 2015, 53, 1622-1627.	1.8	122
137	Effect of Probiotics (Saccharomyces boulardii) on Microbial Translocation and Inflammation in HIV-Treated Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 256-263.	0.9	109
138	Clinical and economic impact of urinary tract infections caused by ESBL-producing Escherichia coli requiring hospitalization: A matched cohort study. Journal of Infection, 2015, 71, 667-674.	1.7	58
139	Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain. Future Microbiology, 2015, 10, 1145-1154.	1.0	6
140	Conventional and molecular diagnostic strategies for prosthetic joint infections. Expert Review of Molecular Diagnostics, 2014, 14, 83-96.	1.5	24
141	Future alternatives for the treatment of infections caused by carbapenemase-producing Enterobacteriaceae: What is in the pipeline?. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2014, 32, 56-60.	0.3	3
142	Effective removal of colistin methanesulphonate and formed colistin during intermittent haemodialysis in a patient infected by polymyxin-only-susceptiblePseudomonas aeruginosa. Journal of Chemotherapy, 2014, 26, 122-124.	0.7	10
143	Lack of association between genotypes and haematogenous seeding infections in a large cohort of patients with methicillin-resistant Staphylococcus aureus bacteraemia from 21 Spanish hospitals. Clinical Microbiology and Infection, 2014, 20, 361-367.	2.8	14
144	Gram-negative prosthetic joint infection: outcome of a debridement, antibiotics and implant retention approach. A large multicentre study. Clinical Microbiology and Infection, 2014, 20, O911-O919.	2.8	172

#	Article	IF	Citations
145	Surfactant protein A genetic variants associate with severe respiratory insufficiency in pandemic influenza A virus infection. Critical Care, 2014, 18, R127.	2.5	58
146	Conservative Treatment of an Epidural Abscess After Thoracic Epidural Catheterization. A $\&$ A Case Reports, 2014, 3, 162-165.	0.7	1
147	Advantages of sonication fluid culture for the diagnosis of prosthetic joint infection. Journal of Infection, 2014, 69, 35-41.	1.7	108
148	Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain. Clinical Microbiology and Infection, 2014, 20, O245-O254.	2.8	241
149	Plasma and cerebrospinal fluid concentrations of linezolid in neurosurgical critically ill patients with proven or suspected central nervous system infections. International Journal of Antimicrobial Agents, 2014, 44, 409-415.	1.1	47
150	Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented. Current Infectious Disease Reports, 2014, 16, 439.	1.3	9
151	Initial Use of Echinocandins Does Not Negatively Influence Outcome in Candida parapsilosis Bloodstream Infection: A Propensity Score Analysis. Clinical Infectious Diseases, 2014, 58, 1413-1421.	2.9	104
152	Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin. Journal of Antimicrobial Chemotherapy, 2014, 69, 568-571.	1.3	56
153	Mannose-binding lectin gene variants and infections in patients receiving autologous stem cell transplantation. BMC Immunology, 2014, 15, 17.	0.9	9
154	Predictive factors of severe multilobar pneumonia and shock in patients with influenza. Emergency Medicine Journal, 2014, 31, 301-307.	0.4	3
155	Risk factors and effectiveness of preventive measures against influenza in the community. Influenza and Other Respiratory Viruses, 2013, 7, 177-183.	1.5	25
156	Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents, 2013, 42, 178-181.	1.1	15
157	Prosthesis Failure Within 2 Years of Implantation Is Highly Predictive of Infection. Clinical Orthopaedics and Related Research, 2013, 471, 3672-3678.	0.7	93
158	Infection due to Actinobaculum spp: Report of 12 patients in Spain. Journal of Infection, 2013, 66, 107-109.	1.7	13
159	Healthcare-associated, community-acquired and hospital-acquired bacteraemic urinary tract infections in hospitalized patients: a prospective multicentre cohort study in the era of antimicrobial resistance. Clinical Microbiology and Infection, 2013, 19, 962-968.	2.8	104
160	Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infectious Diseases, 2013, 13, 380.	1.3	179
161	Inappropriate use of antibiotics in hospitals: The complex relationship between antibiotic use and antimicrobial resistance. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2013, 31, 3-11.	0.3	68
162	The Use of Erythromycin and Colistin-Loaded Cement in Total Knee Arthroplasty Does Not Reduce the Incidence of Infection. Journal of Bone and Joint Surgery - Series A, 2013, 95, 769-774.	1.4	79

#	Article	IF	CITATIONS
163	Sonication versus Vortexing of Implants for Diagnosis of Prosthetic Joint Infection. Journal of Clinical Microbiology, 2013, 51, 591-594.	1.8	92
164	Globally Expanding Carbapenemase Finally Appears in Spain: Nosocomial Outbreak of Acinetobacter baumannii Producing Plasmid-Encoded OXA-23 in Barcelona, Spain. Antimicrobial Agents and Chemotherapy, 2013, 57, 5155-5157.	1.4	50
165	A Large Multicenter Study of Methicillin–Susceptible and Methicillin–Resistant Staphylococcus aureus Prosthetic Joint Infections Managed With Implant Retention. Clinical Infectious Diseases, 2013, 56, 182-194.	2.9	319
166	Implant sonication increases the diagnostic accuracy of infection in patients with delayed, but not early, orthopaedic implant failure. Bone and Joint Journal, 2013, 95-B, 244-249.	1.9	84
167	The relationship between microbiology results in the second of a two-stage exchange procedure using cement spacers and the outcome after revision total joint replacement for infection. Journal of Bone and Joint Surgery: British Volume, 2012, 94-B, 249-253.	3.4	73
168	Prognosis of hospitalized patients with 2009 H1N1 influenza in Spain: influence of neuraminidase inhibitors. Journal of Antimicrobial Chemotherapy, 2012, 67, 1739-1745.	1.3	19
169	Impact of empirical treatment in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. bacteremia. A multicentric cohort study. BMC Infectious Diseases, 2012, 12, 245.	1.3	75
170	Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Services Research, 2012, 12, 122.	0.9	113
171	Multiplex PCR of sonication fluid accurately differentiates between prosthetic joint infection and aseptic failure. Journal of Infection, 2012, 65, 541-548.	1.7	155
172	Eosinophil Count and Neutrophil-Lymphocyte Count Ratio as Prognostic Markers in Patients with Bacteremia: A Retrospective Cohort Study. PLoS ONE, 2012, 7, e42860.	1.1	129
173	Community-onset healthcare-related urinary tract infections: Comparison with community and hospital-acquired urinary tract infections. Journal of Infection, 2012, 64, 478-483.	1.7	64
174	Effectiveness of hand hygiene and provision of information in preventing influenza cases requiring hospitalization. Preventive Medicine, 2012, 54, 434-439.	1.6	52
175	Systemic Bartonella henselae infection and Crohn $\hat{E}^{1}\!\!/\!\!4$ s disease treatment with infliximab. Inflammatory Bowel Diseases, 2012, 18, E197-E198.	0.9	8
176	High prevalence of upper urinary tract involvement detected by 111 indium-oxine leukocyte scintigraphy in patients with candiduria. European Journal of Clinical Microbiology and Infectious Diseases, 2012, 31, 237-242.	1.3	5
177	Intra- and inter-species spread of carbapenemase genes in a non-hospitalized patient. European Journal of Clinical Microbiology and Infectious Diseases, 2011, 30, 1551-1555.	1.3	9
178	Efficacy of Influenza A H1N1/2009 Vaccine in Hemodialysis and Kidney Transplant Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2208-2214.	2,2	60
179	Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case–control study. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 335-339.	1.3	46
180	Clinical Features of Infections and Colonization by <i>Acinetobacter</i> Genospecies 3. Journal of Clinical Microbiology, 2010, 48, 4623-4626.	1.8	12

#	Article	IF	CITATIONS
181	Spread of plasmids containing the blaVIM-1 and blaCTX-M genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. Journal of Antimicrobial Chemotherapy, 2010, 65, 661-665.	1.3	62
182	Communityâ€Onset Bacteremia Due to Extendedâ€Spectrum βâ€Lactamase–Producing <i>Escherichia coli:</i> Risk Factors and Prognosis. Clinical Infectious Diseases, 2010, 50, 40-48.	2.9	294
183	Off-label prescription of tigecycline: clinical and microbiological characteristics and outcomes. International Journal of Antimicrobial Agents, 2010, 36, 471-472.	1.1	11
184	Pharmacokinetics of linezolid in human non-inflamed vitreous after systemic administration. Journal of Antimicrobial Chemotherapy, 2009, 63, 550-552.	1.3	18
185	Escherichia coli producing SHV-type extended-spectrum Â-lactamase is a significant cause of community-acquired infection. Journal of Antimicrobial Chemotherapy, 2009, 63, 781-784.	1.3	24
186	Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection, 2009, 37, 461-465.	2.3	87
187	High Prevalence of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in Bacteremia After Transrectal Ultrasound-guided Prostate Biopsy: A Need for Changing Preventive Protocol. Urology, 2009, 74, 1195-1199.	0.5	44
188	Polymorphic Receptors of the Innate Immune System (MBL/MASP-2 and TLR2/4) and Susceptibility to Pneumococcal Bacteremia in HIV-Infected Patients: A Case-Control Study. Current HIV Research, 2009, 7, 218-223.	0.2	14
189	Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903. Clinical Infectious Diseases, 2008, 47, 1083-1092.	2.9	34
190	Community Infections Caused by Extended-Spectrum β-Lactamase–Producing Escherichia coli. Archives of Internal Medicine, 2008, 168, 1897.	4.3	333
191	Is Mannoseâ€Binding Lectin Deficiency Associated with Infection due to Gramâ€Positive Bacteria?. Clinical Infectious Diseases, 2008, 47, 1492-1493.	2.9	7
192	Endogenous ocular candidiasis: Changes in epidemiology and factors associated with poor functional outcome. Scandinavian Journal of Infectious Diseases, 2007, 39, 225-230.	1.5	3
193	Association between Mannose-Binding Lectin Deficiency and Septic Shock following Acute Pyelonephritis Due to Escherichia coli. Vaccine Journal, 2007, 14, 256-261.	3.2	23
194	Biofilm Formation in Uropathogenic Escherichia coli Strains: Relationship With Prostatitis, Urovirulence Factors and Antimicrobial Resistance. Journal of Urology, 2007, 177, 365-368.	0.2	170
195	Invasive Cryptococcosis and Adalimumab Treatment. Emerging Infectious Diseases, 2007, 13, 953-955.	2.0	26
196	Acquisition of Multidrug-ResistantSerratia marcescensby Critically III Patients Who Consumed Tap Water During Receipt of Oral Medication. Infection Control and Hospital Epidemiology, 2006, 27, 774-777.	1.0	22
197	Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units*. Critical Care Medicine, 2006, 34, 329-336.	0.4	97
198	Implication of biofilm formation in the persistence of urinary tract infection caused by uropathogenic Escherichia coli. Clinical Microbiology and Infection, 2006, 12, 1034-1036.	2.8	131

#	Article	IF	Citations
199	Clinical Consequences of Infection in Patients With Acute Stroke. Stroke, 2006, 37, 461-465.	1.0	134
200	Extended Virulence Genotypes and Phylogenetic Background of Escherichia colilsolates from Patients with Cystitis, Pyelonephritis, or Prostatitis. Journal of Infectious Diseases, 2005, 191, 46-50.	1.9	151
201	Cephalosporin-induced Nonconvulsive Status Epilepticus: Clinical and Electroencephalographic Features. Epilepsia, 2005, 46, 1550-1552.	2.6	70
202	Novel MASP2 variants detected among North African and Sub-Saharan individuals. Tissue Antigens, 2005, 66, 131-135.	1.0	28
203	Quinolone-Resistant Uropathogenic Escherichia coli Strains from Phylogenetic Group B2 Have Fewer Virulence Factors than Their Susceptible Counterparts. Journal of Clinical Microbiology, 2005, 43, 2962-2964.	1.8	99
204	Expression of Interleukin-8 Receptors (CXCR1 and CXCR2) in Premenopausal Women with Recurrent Urinary Tract Infections. Vaccine Journal, 2005, 12, 1358-1363.	3.2	40
205	The Early Systemic Prophylaxis of Infection After Stroke Study. Stroke, 2005, 36, 1495-1500.	1.0	176
206	Evaluation of Inflammatory and Renal-Injury Markers in Women Treated with Antibiotics for Acute Pyelonephritis Caused by Escherichia coli. Vaccine Journal, 2004, 11, 142-146.	2.6	18
207	Type 1 Integrons in Epidemiologically Unrelated Acinetobacter baumannii Isolates Collected at Spanish Hospitals. Antimicrobial Agents and Chemotherapy, 2004, 48, 364-365.	1.4	30
208	Clinical Features and Epidemiology of Acinetobacter baumannii Colonization and Infection in Spanish Hospitals. Infection Control and Hospital Epidemiology, 2004, 25, 819-824.	1.0	130
209	Accurate topographical diagnosis of urinary tract infection in male patients with 111indium-labelled leukocyte scintigraphy. European Journal of Internal Medicine, 2004, 15, 157-161.	1.0	14
210	Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case-control study. Journal of Internal Medicine, 2003, 254, 280-286.	2.7	28
211	Blood Cultures for Women with Uncomplicated Acute Pyelonephritis: Are They Necessary?. Clinical Infectious Diseases, 2003, 37, 1127-1130.	2.9	106
212	A nosocomial outbreak of influenza during a period without influenza epidemic activity. European Respiratory Journal, 2003, 21, 303-307.	3.1	105
213	Addition of a Macrolide to a βâ€Lactam–Based Empirical Antibiotic Regimen Is Associated with Lower Inâ€Hospital Mortality for Patients with Bacteremic Pneumococcal Pneumonia. Clinical Infectious Diseases, 2003, 36, 389-395.	2.9	355
214	Transrectal Prostatic Ultrasonography in Acute Bacterial Prostatitis: Findings and Clinical Implications. Scandinavian Journal of Infectious Diseases, 2003, 35, 114-120.	1.5	33
215	Bacteraemia in adults due to glucose non-fermentative Gram-negative bacilli other than P. aeruginosa. QJM - Monthly Journal of the Association of Physicians, 2003, 96, 227-234.	0.2	40
216	Acute pyelonephritis in adults. Reviews in Medical Microbiology, 2003, 14, 119-127.	0.4	2

#	Article	IF	CITATIONS
217	Title is missing!. Clinical Nuclear Medicine, 2003, 28, 403-404.	0.7	O
218	Short-term effectiveness of ceftriaxone single dose in the initial treatment of acute uncomplicated pyelonephritis in women. A randomised controlled trial. Emergency Medicine Journal, 2002, 19, 19-22.	0.4	37
219	Differences in Virulence Factors among Clinical Isolates of Escherichia coli Causing Cystitis and Pyelonephritis in Women and Prostatitis in Men. Journal of Clinical Microbiology, 2002, 40, 4445-4449.	1.8	161
220	Are Quinoloneâ€Resistant UropathogenicEscherichia coliLess Virulent?. Journal of Infectious Diseases, 2002, 186, 1039-1042.	1.9	155
221	Molecular epidemiology and evolution of resistance to quinolones in Escherichia coli after prolonged administration of ciprofloxacin in patients with prostatitis. Journal of Antimicrobial Chemotherapy, 2002, 49, 55-59.	1.3	40
222	111Indium labelled leukocyte scintigraphy in the detection of acute prostatitis. Nuclear Medicine Communications, 2002, 23, 1137-1142.	0.5	14
223	Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation, 2002, 74, 1381-1386.	0.5	89
224	Decreased Invasive Capacity of Quinoloneâ€ResistantEscherichia coliin Patients with Urinary Tract Infections. Clinical Infectious Diseases, 2001, 33, 1682-1686.	2.9	75
225	Mixed cryoglobulinaemia in patients with chronic hepatitis C infection: prevalence, significance and relationship with different viral genotypes. Annals of Medicine, 1999, 31, 352-358.	1.5	38
226	Systemic AA amyloidosis induced by oral contraceptiveâ€associated hepatocellular adenoma: a 13â€year follow up. Liver, 1995, 15, 164-167.	0.1	15
227	Low Zinc Levels at Clinical Admission Associates with Poor Outcomes in COVID-19. SSRN Electronic Journal, 0, , .	0.4	3
228	Comparison of Ceftolozane/Tazobactam Infusion Regimens in a Hollow-Fiber Infection Model against Extensively Drug-Resistant Pseudomonas aeruginosa Isolates. Microbiology Spectrum, 0, , .	1.2	1